Figure 2: Screening for potential protein, miRNA and microbiome biomarkes in patients with atopic dermatitis. A) Heatmap of 4 atopic dermatitis serum samples before (blue column) and 6 months after (teal column) systemic therapy with dupilumab, unsupervised complete hierarchical clustering with euclidean distances. B)Histogram of effect size estimates between all 440 screened proteins (pre vs 6-month post initiation of dupilumab therapy) expressed in Hedge’s G values. Candidate proteins were identified as showing the Hedge’s G value either higher than 0.9 or lower than -0.9. C)Heatmap of 60 most differentially expressed miRNAs in serum using next generation sequencing in AD patients before (blue) and after (teal) systemic therapy applying unsupervised hierarchical clustering with euclidean distances. Additional 6 healthy control samples (top row green were provided for completeness D) Principal component analysis of the scaled and centered (uncurated) Next-Generation-Sequencing data shows a separation of AD-derived samples from healthy individuals.E) Volcano plot of differentially expressed miRNAs. Red dots indicate log2 fold change < -1. F) Relative abundance of 10 most abundant skin microbiota in 7 AD patients and 7 healthy individuals measured by sequencing of 3rd to 4th hypervariable regions of 16S ribosomal RNA by NGS.